Yes, any other S1 agonist has to go through the full approval process as we did. For new bandwagon candidates, that means a lot of time, from IND. For any current experimental S1 agonists already in clinicals, from P2. And they're not necessarily going to be effective. Only advanced clinical trials can show this. (Lo and behold, this why we have to do it too. No fool-proof animal models, no fantasy "Anavex now".)
The payoff is high. Success attracts competition. It's a good problem to have, and not completely avoidable.
News 
Market Data 
Discover 
